Of note, in high-risk patients bearing del17p, del11q, or TP53 mutations, the ORR was 95%.27 A phase 3 trial (GENUINE, NCT02301156) of ublituximab plus ibrutinib in high-risk relapsed or refractory CLL reported an ORR of 78% for the combination arm vs 45% for the monotherapy arm.28 The combination of ublituximab and umbralisib with/without ibrutinib had indicated tolerability and activity in patients with relapsed or refractory B-NHLs and CLL in a phase 1 study (NCT02006485).29,30. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.